TABLE 3.
Performance of the blood small EV miR‐95‐3p/miR‐26b‐5p combined with serum levels of CA19‐9 in the training cohort and test cohort
| Predicted PDAC | Predicted CP | Sensitivity (%) | Specificity (%) | |
|---|---|---|---|---|
| Training cohort | ||||
| PPDAC (30) | 29 | 1 | 96.7 | 100 |
| CP (18) | 0 | 18 | ||
| Test cohort | ||||
| PPDAC (27) | 26 | 1 | 96.3 | 92.8 |
| CP (14)a | 1 | 13 |
a
Because 14 out of 15 patients had the expression data of both blood small EV miRNAs and serum CA19‐9 levels in the validation cohort, they were included.
Abbreviations: CP, chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma.